NCT04975438View on ClinicalTrials.gov

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

December 19, 2022

Study Completion Date

March 13, 2023

Conditions
Dermatitis, Atopic
Interventions
DRUG

GSK1070806

GSK1070806 will be administered

DRUG

Placebo

Placebo will be administered

Trial Locations (11)

19103

GSK Investigational Site, Philadelphia

33155

GSK Investigational Site, Miami

33613

GSK Investigational Site, Tampa

48084

GSK Investigational Site, Troy

72117

GSK Investigational Site, North Little Rock

73118

GSK Investigational Site, Oklahoma City

77479

GSK Investigational Site, Sugar Land

78218

GSK Investigational Site, San Antonio

T6G 1C3

GSK Investigational Site, Edmonton

N6A 5R9

GSK Investigational Site, London

N6H 5L5

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04975438 - Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis | Biotech Hunter | Biotech Hunter